Short Interest in Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Decreases By 7.8%

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,377,300 shares, a decrease of 7.8% from the December 31st total of 1,494,600 shares. Based on an average trading volume of 100 shares, the short-interest ratio is presently 13,773.0 days.

Swedish Orphan Biovitrum AB (publ) Price Performance

BIOVF traded up $2.18 during trading on Friday, reaching $30.48. The company’s stock had a trading volume of 121 shares, compared to its average volume of 14. The company has a market cap of $10.85 billion, a price-to-earnings ratio of 51.66 and a beta of 0.51. The firm has a fifty day simple moving average of $28.15 and a two-hundred day simple moving average of $28.56. Swedish Orphan Biovitrum AB has a 1 year low of $22.87 and a 1 year high of $32.25. The company has a quick ratio of 0.49, a current ratio of 0.73 and a debt-to-equity ratio of 0.30.

Analyst Upgrades and Downgrades

Separately, Barclays upgraded Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a research report on Wednesday, January 8th.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.